Novosti
Khirurgii

 This journal is
indexed in Scopus
journal cover
android icon Android Applicaion

Year 2009 Vol. 17 No 4

LECTURES, REVIEWS

ZHEBENTYAEV A.A., GOLDYTSKY S.O.

PRESENT-DAY DIAGNOSTICS AND TREATMENT METHODS OF ERECTILE DYSFUNCTION

The researches in the erectile dysfunction (ED) made during the last 15 years have led to the development of several new treatment options and strategies for ED. Worldwide availability of the three oral PDE 5 inhibitors (sildenafil, tadalafil, vardenafil) are associated with high efficacy and safety rates, even in difficult-to-treat populations (e.g. diabetes mellitus, radical prostatectomy). Many physicians without background knowledge and clinical experience of the diagnosis and treatment of ED are involved in decision-making concerning the evaluation and treatment of these men. Treatment options for patients not responding to oral drugs (or with contraindications) include intracavernous injections, intraurethral alprostadil, vacuum constriction devices and implantation of penile prosthesis. It must be emphasized that the physician should warn the patient that sexual intercourse is considered to be a high physical activity, which increases the heart rate as well as cardiac work. Physicians should assess the cardiac risks of patients prior to treating ED. Reconstructive vascular surgery is associated with poor outcomes in long-term follow-up. Further studies are underway. Data of numerous investigations have led to creation of standards of diagnostics and treatment of ED of the European Association of Urology (EAU-2009).

Keywords: erectile dysfunction, methods of diagnostics, standards of treatment, 5 PDE blockers
p. 150 – 159 of the original issue
References
  1. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’ / M. Braun [et al.] // Int. J. Impot. Res. – 2000. – Vol. 12. – P. 305-311.
  2. Physiology of erection and pharmacological management of impotence / T. F. Lue [et al.] // J. Urol. – 1987. – Vol. 137. – P. 829-836.
  3. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? / C. A. Derby [et al.] // Urology. – 2000. – Vol. 56. – P. 302-306.
  4. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction / B. Davis-Joseph [et al.] // Urology. – 1995. – Vol. 45. – P. 498-502.
  5. Epidemiology of erectile dysfunction / R. W. Lewis [et al.] // Urol. Clin. North Am. – 2001. – Vol. 28. – P. 209-216.
  6. The international index of erectile function (IIEF): a multidimentional scale for assessment of erectile dysfunction / R. C. Rosen [et al.] // Urology. – 1997. – Vol. 49. – P. 822-830.
  7. Diagnostic steps in the evaluation of patients with erectile dysfunction / D. Hatzichristou [et al.] // J. Urol. – 2002. – Vol. 168. – P. 615-620.
  8. Summary of the recommendations on sexual dysfunction in men / T. F. Lue [et al.] // J. Sexual Medicine. – 2004. – Vol. 1. – P. 6-23.
  9. Management of sexual dysfunction in patients with cardiovascular diseases: recommendations of the Princeton Consensus Panel / R. DeBusk [et al.] // Am. J. Cardiol. – 2000. – Vol. 86. – P. 62-68.
  10. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect on sexual intercourse / D. G. Hatzichristou [et al.] // J. Urol. – 1998. – Vol. 159. – P. 1921-1926.
  11. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction / E. J. Meuleman [et al.] // Urol. Clin. North Am. – 1995. – Vol. 22. – P. 803-819.
  12. Clinical evaluation and management strategy for sexual dysfunction in men and women / D. Hatzichristou [et al.] // J. Sexual Medicine. – 2004. – Vol. 1. – P. 49-57.
  13. Hormonal erectile dysfunction. Evaluation and management / A. Morales [et al.] // Urol. Clin. North Am. – 2001. – Vol. 28. – P. 279-288.
  14. Venous impotence: pathophysiology, diagnosis and treatment / E. Wespes [et al.] // J. Urol. – 1993. – Vol. 149. – P. 1238-1245.
  15. Psychogenic erectile dysfunction. Classification and management / R. C. Rosen [et al.] // Urol. Clin. North Am. – 2001. – Vol. 28. – P. 269-278.
  16. Erectile dysfunction / T. F. Lue [et al.] // N. Engl. J. Med. – 2000. – Vol. 342. – P. 1802-1813.
  17. Sildenafil: a review of its use in erectile dysfunction / H. D. Langtry [et al.] // Drugs. – 1999. – Vol. 57. – P. 967-989.
  18. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial / B. G. Stuckey [et al.] // Diabetes Care. – 2003. – Vol. 26. – P. 279-284.
  19. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy / R. Raina [et al.] // Urology. – 2004. – Vol. 63. – P. 960-966.
  20. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial / H. Porst [et al.] // Urology. – 2003. – Vol. 62. – P. 121-125.
  21. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction / F. Montorsi [et al.] // Eur. Urol. – 2004. – Vol. 45. – P. 339-344.
  22. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial / F. Montorsi [et al.] // J. Urol. – 2004. – Vol. 172. – P. 1036-1041.
  23. Vardenafil: a review of its use in erectile dysfunction / G. M. Keating [et al.] // Drugs. – 2003. – Vol. 63. – P. 2673-2703.
  24. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial / H. Porst [et al.] // Int. J. Impot. Res. – 2001. – Vol. 13. – P. 192-199.
  25. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters / R. A. Kloner [et al.] // Clin. Cardiol. – 2004. – Vol. 27. – P. 120-125.
  26. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia / S. M. Auerbach [et al.] // Urology. – 2004. – Vol. 64. – P. 998-1003.
  27. Apomorphine: an update of clinical trial results / J. P. Heaton [et al.] // Int. J. Impot. Res. – 2000. – Vol. 12. – P. 67-73.
  28. Pharmacotherapy for erectile dysfunction / H. Padma-Nathan [et al.] // J. Sexual Medicine. – 2004. – Vol. 1. – P. 128-140.
  29. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction / C. Teloken [et al.] // J. Urol. – 1998. – Vol. 159. – P. 122-124.
  30. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial / R. A. Costabile [et al.] // J. Urol. – Vol. 161. – P. 1819-1822.
  31. Goldstain, I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction / I. Goldstain // Int. J. Impot. Res. – 2000. – Vol. 12. – P. 75-80.
  32. A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report / B. Hong [et al.] // J. Urol. – 2002. – Vol. 168. – P. 2070-2073.
  33. Current status of local penile therapy / F. Montorsi [et al.] // Int. J. Impot. Res. – 2002. – Vol. 14. – P. 70-81.
  34. Vacuum constriction and external erection devices in erectile dysfunction / L. A. Levine [et al.] // Urol. Clin. North Am. – 2001. – Vol. 28. – P. 335-341.
  35. Intracavernosal injection and intraurethral therapy for erectile dysfunction / S. Leungwattanakij [et al.] // Urol. Clin. North Am. – 2001. – Vol. 28. – P. 343-354.
  36. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction / O. I. Linet [et al.] // N. Engl. J. Med. – 1996. – Vol. 334. – P. 873-877.
  37. Improved vasoactive drug combination for a pharmacological erection program / A. H. Bennett [et al.] // J. Urol. – 1991. – Vol. 146. – P. 1564-1565.
  38. Treatment of intracorporeal injection non-response with sildenafil alone or in combination with triple agent intracorporeal injection therapy / C. G. McMahon [et al.] // J. Urol. – 1999. – Vol. 162. – P. 1992-1997.
  39. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for erection (MUSE) / H. Padma-Nathan [et al.] // N. Engl. J. Med. – 1997. – Vol. 336. – P. 1-7.
  40. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preffered over intraurethral alprostadil: a comparative, randomized, crossover, multicentre study / R. Shabsigh [et al.] // Urology. – 2000. – Vol. 55. – P. 109-113.
  41. Penile prosthesis implantation / D. K. Montague [et al.] // Urol. Clin. North Am. – 2001. – Vol. 28. – P. 355-361.
  42. Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis / M. V. Tefilli [et al.] // Urology. – 1998. – Vol. 52. – P. 1106-1112.
  43. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment / I. Goldstein [et al.] // J. Urol. – 1997. – Vol. 157. – P. 833-839.
  44. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants / C. C. Carson [et al.] // J. Urol. – 2004. – Vol. 171. – P. 1611-1614.
  45. Long-term experience with salvage of infected penile implants / J. J. Mulcahy [et al.] // J. Urol. – 2000. – Vol. 163. – P. 481-482.
Contacts | ©Vitebsk State Medical University, 2007-2023